Navigation Links
TREATMENT OF PRIMARY LIVER CANCER: SARAH STUDY NOW AVAILABLE FOR ALL ELIGIBLE PATIENTS THROUGHOUT FRANCE
Date:6/24/2013

nicaltrials.gov/ct2/show/NCT01482442) are currently accruing patients. The aim is to recruit 400 patients in France with the following inclusion criteria:[1]

  • Patients with advanced HCC with or without portal vein thrombosis or whose disease has progressed after chemoembolization or recurrence of HCC;
  • No extrahepatic spread;
  • Ineligible for:
    • surgical resection;
    • liver transplantation;
    • radiofrequency ablation.

There is a growing medical interest in radioembolization using yttrium-90 resin microspheres in this patient population, based on a substantial number of open-label single-group studies as well as a large multi-centre European analysis[2] of the long-term outcomes related to survival and safety of radioembolization using SIR-Spheres microspheres in patients with inoperable HCC.  

SIR-Spheres microspheres are approved for use in Australia, the European Union (CE Mark), New Zealand, Switzerland, Turkey and several other countries including in Asia (e.g. India, Korean, Singapore and Hong Kong) for the treatment of unresectable liver tumours.  SIR-Spheres microspheres are indicated in the U.S. for the treatment of unresectable metastatic liver tumors from primary colorectal cancer together with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine).

About Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) occurs in people whose livers have become severely damaged or cirrhotic, due to conditions such as hepatitis and alcoholism.  It is one o
'/>"/>

SOURCE SARAH trialists
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 , A series ... events will change the way retail pharmaceutical companies are ... we use and view pharmacies, Health First Pharmacy is ... to the very trendy public demands of customisation and ... events with various activities for both children and adults ...
(Date:9/30/2014)... Sept. 30, 2014 EXECUTIVE SUMMARY ... Outlook to 2017 - Increasing Demand from Ageing ... of the industry past, present and future outlook. ... Canada market with outlook to 2017. ... supplements. Additionally the sub-segments of the industry, ongoing ...
(Date:9/30/2014)... , September 30, 2014 Investor-Edge ... (NASDAQ: IMMU ), Aeterna Zentaris Inc. (NASDAQ: ... OPK ), Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), ... these five companies can be accessed at: http://investor-edge.com/register ... NASDAQ Composite ended at 4,505.85, down 0.14%, the Dow ...
Breaking Medicine Technology:Health First Pharmacy Redefines 'Pharmacy Retail Experience' 2Health First Pharmacy Redefines 'Pharmacy Retail Experience' 3North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 2North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 3Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 2Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 3Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 4Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 5
... Annual Meeting- , , ... of a randomized phase III study presented at the ... The study in adult patients with hematological malignancies at ... demonstrated that Elitek(R) (rasburicase) significantly reduced plasma uric acid ...
... Analgesic Significantly Reduces Postop Pain, Opioid Use, and ... Standard Pain Medication , ... A Phase II dose escalation study of a ... who underwent total knee arthroplasty, or TKA, showed ...
Cached Medicine Technology:Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 2Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 3Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 4Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 5Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress 2Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress 3Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress 4
(Date:9/30/2014)... Amy Norton HealthDay ... -- Long-acting contraceptive devices should be the first choice ... the American Academy of Pediatrics state. Although most ... two other forms of contraception -- intrauterine devices (IUDs) ... to the academy. And they should be the ...
(Date:9/30/2014)... VA (PRWEB) September 30, 2014 Visit ... of Chestnut Hill and you will find a loving ... together, Amyotrophic Lateral Sclerosis. , Steve was ... or Lou Gehrig’s Disease – just before the couple’s ... primary caregiver. , A new video, “Care, Support ...
(Date:9/30/2014)... Franklin, TN (PRWEB) September 30, 2014 ... millions of people throughout the United States and ... of Parkinson’s Disease are diagnosed each year, adding ... diagnosed with the disease. Approximately 400,000 people in ... 2.3 million worldwide. Add to these statistics the ...
(Date:9/30/2014)... 2014 Pivotal 5, LLC, a proven ... Life Time – The Healthy Way of Life CompanySM ... KettleWorX Group Training . KettleWorX Group Training is a ... offers consumers of all fitness levels a means to ... manner. The rollout to Life Time Athletic destinations will ...
(Date:9/30/2014)... HealthDay Reporter TUESDAY, Sept. 30, 2014 (HealthDay ... the return of a common type of irregular heartbeat known ... percent of those taking fish oil for its omega-3 fatty ... of 16 months, compared to 63.2 percent of those ... the twin ills of inflammation or oxidative stress, which may ...
Breaking Medicine News(10 mins):Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 2Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 3Health News:Hospice Provides Care and Support to Patients and Family Caregivers with ALS 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 3Health News:Pivotal 5 Announces Life Time Fitness As National Destination For KettleWorX Kettlebell Training 2Health News:Pivotal 5 Announces Life Time Fitness As National Destination For KettleWorX Kettlebell Training 3Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 2Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 3
... School of Medicine and colleagues discovered that the Notch ... types, and is also implicated in some cancers, is ... The findings appear this week in Cell Stem Cell, ... bone marrow stem cells. , Notch is one of ...
... the Head and Neck, NEW YORK, April 10 ... plastic and cosmetic surgery for the ethnic,patient, will speak ... day,Continuing Medical Education (CME) Accredited seminar entitled "Patient,Safety in ... 12 at the,University Club of New York., "Facial ...
... Support Event, ALEXANDRIA, Va., April 10 ... (NHDD), will be the largest,effort ever undertaken to ... "With healthcare, ,your decisions matter;, however, others ... Nathan A. Kottkamp, Chair, National,Healthcare Decisions Day. "All ...
... in wine that protect against dementia. This is shown in ... Sweden. , The findings are based on 1,458 women who ... 1968. When they were examined by physicians they were asked ... by selecting from seven categories on a scale from never ...
... - 7,000 deaths a year ... pharmacy error risk, - Half of consumers choose their pharmacies for ... ... One-third of America,s 225,million prescription-takers now report experiencing a prescription ...
... their children to a podiatrist,for foot ailments, BETHESDA, ... bring thousands of adults to doctors, offices every,day. But ... Medical Association (APMA) during April,s Foot Health Awareness,Month, many ... it comes to their children,s feet. In fact, only ...
Cached Medicine News:Health News:Developing cancer treatments directed at critical developmental pathway 2Health News:Dr. Edmund Kwan to Speak on Facial Contouring Among Asian Patients at Cosmetic Surgery Seminar 2Health News:National Healthcare Decisions Day in All 50 States, DC, Puerto Rico, and Internationally 2Health News:Wine may protect against dementia 2Health News:Prescription For Disaster: One-Third of Consumers Experience Prescription Errors, New Survey Finds 2Health News:Prescription For Disaster: One-Third of Consumers Experience Prescription Errors, New Survey Finds 3Health News:Pediatric Survey Reveals Many Parents Neglect Their Children's Feet 2
... racks of 96 tips, Sterilized Diamond- Tips ... Sterilized Diamond Tips are irradiated by gamma-rays ... with a certificate of sterilization, specifying the ... certified free of detectable Rnase, Dnase, DNA, ...
... have been designed to optimize the accuracy ... our tip products is widely recognized by ... has been extended over the years and ... and special tips including filter tips, certified ...
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
For the quantitative determination of luteinizing hormone (LH) concentration in human serum....
Medicine Products: